Introduction: There is an ongoing debate regarding the need to conduct intraoperative defibrillation testing (DFT) at the time of implantable cardioverter-defibrillator (ICD) implantation. To provide sufficiently strong evidence for the feasibility of omitting intraoperative DFT in clinical practice, we conducted a meta-analysis of randomized controlled trials (RCT) comparing patients with DFT and no-DFT. Methods: We systematically searched Medline (via PubMed), ClinicalTrial.gov, the Cochrane Central Register of Controlled Trials, and Embase for studies evaluating DFT vs. no-DFT on ICD implantation with regard to total mortality and arrhythmic death, efficacy of first and any appropriate shock in interrupting ventricular tachycardia (VT)/ ventricular fibrillation (VF), and procedural adverse events. Effect estimates [risk ratio (RR) with 95% confidence intervals (CI)] were pooled using the random-effects model. Results: Our meta-analysis included 4 RCTs comprising 3770 patients (1896 with DFT and 1874 without DFT). Total mortality (RR = 1.00, 95% CI 0.86-1.17; P = 0.98) and arrhythmic death (RR = 1.60, 95% CI 0.46-5.59: P = 0.46) were not statistically different. Both first (RR = 0.94, 95% CI 0.89-0.98; P = 0.004) and any appropriate ICD shock (RR = 0.97, 95% CI 0.95-1.00; P = 0.02) significantly increased the rate of VT/VF interruption in the group with no-DFT in comparison with DFT. Finally, the incidence of adverse events was lower in no-DFT patients (RR = 1.23; 95% CI 1.00-1.51; P = 0.05).
INTRODUCTION
Testing of the implantable cardioverter-defibrillator (ICD) for its ability to correctly sense, detect and terminate ventricular fibrillation (VF) has been an important part of device implantation since procedures in humans began in the early 1980s. In recent years, the advent of the biphasic waveform, better understanding of optimal shock waveform/duration, and higher-shock energy devices, have led some to question the need for defibrillation testing (DFT) [1] . Furthermore, controversy over whether to perform DFT has focused on possible adverse clinical events [1] [2] [3] [4] . A prior systematic review by Phan et al. [5] demonstrates no significant benefit for DFT in terms of mortality, ICD efficacy or 30-day post-implant complications. In this systematic review and meta-analysis, we sought to update the effect of DFT on the risks of all-cause mortality, arrhythmic death, appropriate shock efficacy, and procedural adverse events.
METHODS

This analysis was performed in adherence to the Preferred
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Reporting Items for Systemic reviews and Meta-Analyses (PRISMA) statement on the quality of reporting of meta-analyses [6] ZiғK'p.
Search Strategy
We searched the Medline (via PubMed), ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials for studies of DFT testing in ICD that had been published through June 31, 2017. Medical Subject Headings (MeSH) and keywords included the following: (1) implantable cardioverter-defibrillators, (2) DF test, (3) intra-operative DF testing, (4) ventricular tachycardia, and (5) ventricular fibrillation. In addition, we searched for meeting abstracts in Embase and hand-searched references and related citations in review articles and commentaries.
Study Selection and Eligibility Criteria
The primary outcome was all-cause mortality. Secondary outcomes included arrhythmic death and appropriate shock efficacy. Data on safety included procedural adverse events and complications as defined by the individual studies included. Only randomized studies that followed patients for ≥6 months and in which mortality data were reported or available from the authors were included.
Quality Assessment
The internal validity of included studies was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomized trials [7] . The effect size is presented as relative risk (RR). Statistical heterogeneity was evaluated using the I 2 statistic and its 95% confidence interval (CI) [8] . A sensitivity analysis was performed by estimating the pooled effect sizes after leaving each study out one by one. A two-tailed P ≤ 0.05 was considered statistically significant.
Data Synthesis and Statistical Analysis
RESULTS
Study Selection
Our literature search identified 484 publications (Fig 1) . Sixteen articles were assessed for eligibility. Four RCTs met the inclusion criteria [Shockless IMPLant Evaluation (SIMPLE) [3] , NO Regular Defibrillation testing In Cardioverter Defibrillator Implantation (NORDIC ICD) [9] , Resynchronization for Ambulatory Heart Failure substudy (RAFT DFT) [10] , and Test-No Test Implantable Cardioverter Defibrillator Pilot Study (TNT ICD) [11] ]. These 4 studies included 3770 (1896 DFT and 1874 no-DFT) participants. Table 1 summarizes the characteristics and Fig 2 reported the quality assessment of the studies included. 
Characteristics
The baseline characteristics of the patients are summarized in Table 2 . 
Primary Outcome
All-Cause Mortality
Data on mortality were analyzed in the intention-to-treat cohort. A total of 535 deaths (14.2%) were reported. No significant difference in the risk of death (RR = 1.00, 95% CI 0.86-1.17; P = 0.98) was observed with DFT versus no-DFT (Fig 3) . There was no significant heterogeneity among the 4 studies (I 2 = 0%; P = 0.39). A sensitivity analysis revealed that no individual study had a predominant impact. However, the overall estimated RR increased to 1.24 (95% CI 0.86-1.79; P = 0.24) when SIMPLE was excluded.
Secondary Outcomes
TNT ICD did not report the number of patients with arrhythmic death, and the number of first or any appropriate shock efficacy; so, the study was removed from the analyses.
Arrhythmic Death
Arrhythmic death occurred in 144 patients (3.9%) and was similar between groups (RR = 1.60, 95% CI 0.46-5.59: P = 0.46) (Fig 4) . There was no significant heterogeneity among the included studies (I 2 = 45%; P = 0.18). On sensitivity analysis, while no individual study had a predominant impact, the overall estimated RR increased to 4.97 (95% CI 0.58-42.42; P = 0.14) when SIMPLE was excluded.
Shock Efficacy
The analyses yielded the pooled effect-estimate in the on-treatment cohort. During follow-up, appropriate shock efficacy was reduced in the DFT group compared with the no-DFT group, with a statistically significant difference (RR = 0.97, 95% CI 0.95-1.00; P = 0.02) (Fig 5) . When we considered the first appropriate ICD shock, the pooled effect-estimate indicated a somewhat lower efficacy in the no-DFT group (RR = 0.94, 95% CI 0.89-0.98; P = 0.004) (Fig 6) . The sensitivity analysis suggested that NORDIC ICD had the greatest impact on statistical significance, and the overall estimated RR decreased to 0.96 (95% CI 0.90-1.02; P = 0.17) when the study was omitted. 
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Safety Outcomes
A total of 327 patients had procedural adverse events and complications related to ICD implantation, 181 of whom had undergone DFT and 146 had not (RR = 1.23; 95% CI 1.00-1.51; P = 0.05) (Fig 7) . There was no statistical heterogeneity among the studies (I 2 = 0%; P = 0.86). On sensitivity analysis, two studies had a major impact on the statistical analysis; the overall estimated RR decreased to 1.18 (95% CI 0.87-1.60; P = 0.27) when NORDIC ICD was excluded, and increased to 1.28 (95% CI 0.97-1.68; P = 0.08) when SIM-PLE was omitted. The 30-day procedure-related mortality rate was 0.3% in the DFT group and 0.5% in the no-DFT group (RR = 0.69, 95% CI 0.25 -1.88; P = 0.46). The procedure-related stroke rate was 0.2% in patients with DFT and 0.4% in those without DFT (RR = 0.61, 95% CI 0.17 -2.25; P = 0.46). Finally, intraoperative hypotension was the only adverse event somewhat more frequent in patients with DFT (1.1% vs. 0.3%; RR = 3.83, 95% CI 0.69 -21.31; P = 0.13).
DISCUSSION
Findings
The findings from our systematic review and meta-analysis suggest that DFT at the time of ICD implantation has no impact on all-cause mortality or arrhythmic death during follow-up. Unexpectedly, the effect estimate reveals a 2% to 11% statistically significant lower first appropriate shock efficacy in the group with DFT versus those with no-DFT. This outcome was greatly influenced by the results of NORDIC ICD, which used higher programmed first shock energy (40 J) than SIMPLE (31J) and RAFT DFT (25J). Furthermore, a reduction was found in any appropriate shock efficacy in interrupting ventricular arrhythmias in the DFT group. This result was not affected by any single study, as the shocks delivered after the first were programmed to the maximum energy (from 31 J to 41 J) and did not differ greatly in number in the included studies. RAFT DFT, SIMPLE, NORDIC ICD, and TNT ICD demonstrated similar modest increases in overall procedural safety outcomes, which did not quite reach statistical significance in any individual trial. When we pooled the data, DFT was associated with a statistically significant 23% increased risk of total procedural adverse events and complications. This result was mainly driven by a single adverse event (intraoperative hypotension).
Strengths of our Analysis
To the best of our knowledge, this is the first systematic review and meta-analysis of RCTs to compare the efficacy and safety of DFT at time of ICD implantation. Our results are consistent with previous observational data [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and meta-analyses [5, 23] and provide further support to the recommendation to omit defibrillation efficacy testing in patients undergoing initial transvenous ICD implantation procedures [24] . Nonetheless, these results do not apply to specific subgroups, which were excluded or poorly represented in this meta-analysis, such as patients with right-sided ICD pocket or non-transvenous systems; patients with congenital heart diseases, channelopathies or hypertrophic cardiomyopathy; and patients who undergo device replacement. Ventricular fibrillation is induced during ICD implantation to assess: (1) electrical integrity of the connections between the leads and pulse generator; (2) reliable sensing, detection, and redetection in VF; and (3) optimal, or at least adequate, programmed shock strength. Low voltage pulses or shocks in normal rhythm can achieve the first goal. Concerning the second point, several studies have demonstrated a strong correlation between R wave amplitude in native rhythm and reliable sensing during induced and spontaneous VF. If the R wave during native rhythm is ≥5-7 mV, sensing during VF is almost always sufficient to ensure rapid detection or redetection [25, 26] . Based on these considerations, the issue of
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whether to perform DFT is confined to the third point. Assessing the value of DFT requires considering four questions: (1) Does it predict shock success for induced VF? (2) Does it predict shock success for spontaneous VT/VF? (3) What is the relationship between DFT and conversion of spontaneous ventricular tachyarrhythmias? (4) Does it predict total mortality or sudden death? The studies included in our meta-analysis used a 10 J "safety-margin" criterion on implantation. This method limits testing to the minimum number of induced episodes necessary to determine whether there is a sufficient safety-margin (i.e. 10 J) between the maximum shock strength of the ICD and the shock strength required for consistent defibrillation. Data from the studies indicate that an extremely high number of patients (97.1%) were successfully defibrillated at the tested shock strength. While device revision provided no benefit during follow-up, patients in the DFT group underwent unnecessary system revision and/or ICD reprogramming [27] . The primary assumption of intraoperative DFT is that successful defibrillation on implantation will predict successful treatment of clinical ventricular arrhythmias. Our results indicate that the efficacy of the firstshock in interrupting spontaneous rapid VT or VF ranged from 87.0% in the DFT patients to 93.2% in the no-DFT group. This observation suggests that shocks for spontaneous VT/VF may not be effective for reasons that are not evaluated on implantation, therefore negating the utility of DFT. Furthermore, the first-shock success rate in spontaneous VT/VF has a weak relationship with the total conversion rate for VT/VF. Implantable cardioverter-defibrillators deliver up to six or eight shocks for VT/VF at maximum strength, so that subsequent shocks may succeed if the first fails, and better implant testing did not reduce overall shock efficacy. Finally, DFT had a neutral effect on mortality. Data regarding the relationship between ICD implant testing and either total mortality or arrhythmic death are limited and difficult to interpret for several reasons. Factors that cannot be tested on implantation probably cause some failed shocks or sudden death. Such factors include ischemia, progressive heart failure, metabolic abnormalities, drug effects, and ICD lead or generator failures. Further, it is difficult to establish how often a high DFT is caused by an inadequate ICD system, and how often it is an indirect marker of a "sicker" patient. It is reasonable to accept that patients with unreliable defibrillation on implantation have a clinically higher risk of sudden death. Finally, some sudden cardiac deaths in ICD patients are caused by malfunctions of ICD leads or pulse generators, which are undetectable at time of implantation [28, 29] . Another important question for this review concerns the risks of defibrillation on implantation. The risks of DFT include those related to induction of VF and those related to shocks alone. The anesthesia required for the delivery of shocks is another potential cause of complications. Data from our meta-analysis indicate that adverse events and complications following ICD implantation are uncommon, and rarely lead to death or permanent disability. Therefore, specific complications that occurred more frequently in patients with DFT were typically short-lived, such as intraoperative hypotension.
Limitations
The results of our meta-analysis are weakened by limitations inherent in meta-analyses and in the included studies. The low number of studies included meant that statistical power was low, especially for safety data analysis. The analysis of rare events carries its own limitations, in that even a small change in the number of events can produce a dramatic change in the results. Our pooled effect estimate included trials that differed in terms of follow-up. NORDIC ICD had a shorter follow-up than SIMPLE (22.8 versus 37 months) and, although the patient populations in the two studies were comparable, the overall mortality rate was lower in NORDIC ICD, which is indicative of a "less sick" patient cohort. RAFT DFT had a follow-up comparable with that of NORDID ICD, but included only patients in NYHA II functional class. It is noteworthy that NORDIC ICD collected data not only on protocol-specified complications but also on all procedureand patient-related adverse events, which may have affected the results of our safety analysis. Finally, there was a lack of detailed information on intra-operative complications in NORDIC ICD and TNT ICD. SIMPLE and NORDIC ICD reported losses to follow-up that were greater in each trial's no-DFT group, though the overall difference of being lost to follow-up was not statistically significant (RR = 1.62; 95% CI 0.90 -2.93; P = 0.11). This meta-analysis demonstrated that routine DFT at the time of ICD implantation was substantially safe, but did not improve shock efficacy or reduce mortality in comparison with the no-testing strategy. It is therefore expected that the results of the meta-analysis will lead to abandonment of the practice of VF testing in selected patients who underwent transvenous ICD implantation.
